John Docherty
John Docherty, M. Sc., is president and chief operating officer at Helix BioPharma.
Articles
Stabilization of Interferon alpha-2b in a Topical Cream
Kim Gaspar;Jinghui Shen;John Docherty;Ravinderjit Batta;Geriene LaBine;Praveen Kumar;Marianna Foldvari
July 2nd 2009The authors describe a proprietary process for producing a stable, topical interferon alpha-2b formulation that can deliver large drug molecules into the skin or mucosa.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: February 23rd 2024 | Updated: December 20th 2024
Europa Perspectives: Helping to Navigate the Regulatory System
Published: December 13th 2024 | Updated: December 20th 2024
FDA Creates CDER Center for Real-World Evidence Innovation
Published: December 5th 2024 | Updated: December 20th 2024
Leveraging Advancements in Bioanalytical Testing
Published: December 7th 2024 | Updated: December 20th 2024
Exploring Opportunities for LNP Delivery in mRNA
